Last reviewed · How we verify
Efavirenz or Nevirapine
Efavirenz and Nevirapine are non-nucleoside reverse transcriptase inhibitors (NNRTIs) that block HIV reverse transcriptase, preventing the virus from converting its RNA genome into DNA and replicating.
Efavirenz and Nevirapine are non-nucleoside reverse transcriptase inhibitors (NNRTIs) that block HIV reverse transcriptase, preventing the virus from converting its RNA genome into DNA and replicating. Used for HIV-1 infection (as part of combination antiretroviral therapy).
At a glance
| Generic name | Efavirenz or Nevirapine |
|---|---|
| Also known as | Stocrin, Sustiva, Viramune, Sustiva (efavirenz), Viramune (nevirapine) |
| Sponsor | University of Aarhus |
| Drug class | Non-nucleoside reverse transcriptase inhibitor (NNRTI) |
| Target | HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Both drugs bind directly to HIV reverse transcriptase and inhibit its enzymatic activity, blocking a critical step in the HIV replication cycle. They are used as components of combination antiretroviral therapy (cART) to suppress viral replication and prevent disease progression. Efavirenz and Nevirapine are distinct molecules with different pharmacokinetic profiles and resistance patterns, though both belong to the NNRTI class.
Approved indications
- HIV-1 infection (as part of combination antiretroviral therapy)
Common side effects
- Rash
- Dizziness / CNS effects (efavirenz)
- Hepatotoxicity
- Nausea
- Headache
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (PHASE2, PHASE3)
- Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2-Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing Regimen (PHASE2, PHASE3)
- Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024) (PHASE3)
- Antimalarial Pharmacology in Children and Pregnant Women in Uganda
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Efavirenz or Nevirapine CI brief — competitive landscape report
- Efavirenz or Nevirapine updates RSS · CI watch RSS
- University of Aarhus portfolio CI